Current Report Filing (8-k)

Date : 09/27/2019 @ 8:31PM
Source : Edgar (US Regulatory)
Stock : InVivo Therapeutics Holdings Corporation (NVIV)
Quote : 0.448833  -0.028867 (-6.04%) @ 8:59PM
After Hours
Last Trade
Last $ 0.47 ▲ 0.02 (4.72%)

Current Report Filing (8-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 8-K


CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 25, 2019


InVivo Therapeutics Holdings Corp.

(Exact Name of Registrant as Specified in Charter)


Nevada

001‑37350

36‑4528166

(State or Other Jurisdiction
of Incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

 

One Kendall Square, Suite B14402

Cambridge, MA 02139

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (617) 863‑5500

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐     Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12)

☐     Pre-commencement communications pursuant to Rule 14d‑2(b) under the Exchange Act (17 CFR 240.14d‑2(b))

☐     Pre-commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading symbol(s)

    

Name of each exchange on which registered

Common Stock, $0.00001 par value per share

 

NVIV

 

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b‑2 of the Securities Exchange Act of 1934 (§240.12b‑2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) Compensatory Arrangements of Certain Officers

On September 25, 2019, the Board of Directors of InVivo Therapeutics Holdings Corp. (the “Company”) granted, under the Company’s 2015 Equity Incentive Plan, 69,000 shares of restricted Common Stock of the Company, $0.00001 par value per share (“Common Stock”), to Richard Toselli, the Company’s Chief Executive Officer, and 47,500 shares of restricted Common Stock to Richard Christopher, the Company’s  Chief Financial Officer, (together, the “Grants”) in consideration of Dr. Toselli’s and Mr. Christopher’s service as officers of the Company. The Grants vest 100% on September 25, 2022, assuming continued service to the Company by the relevant officer. The Board of Directors also adopted a form of Restricted Stock Agreement under the 2015 Equity Incentive Plan, which form of Restricted Stock Agreement is attached as Exhibit 10.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

INVIVO THERAPEUTICS HOLDINGS CORP.

 

 

Date: September 27, 2019

By:

/s/ Richard Toselli

 

 

Richard Toselli

 

 

Chief Executive Officer

 

InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart

1 Year : From Nov 2018 to Nov 2019

Click Here for more InVivo Therapeutics Charts.

InVivo Therapeutics (NASDAQ:NVIV)
Intraday Stock Chart

Today : Thursday 14 November 2019

Click Here for more InVivo Therapeutics Charts.

Latest NVIV Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.